Vertex Pharmaceuticals (VRTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX)

VRTX 469.90

-1.2%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: MoneyPenny	5/7/2012 4:06:02 PM
	Read Replies (1) of 1169

Vertex Pharmaceuticals (VRTX:$58.12,00$20.71,0055.36%) is up 47.5%, or $17.76, to $55.16 BOSTON (MarketWatch) -- Shares of Vertex Pharmaceuticals (VRTX:$58.12,00$20.71,0055.36%) soared 44% to $54.00 on Monday after it reported positive early data from an on-going Phase II clinical trial testing its new drug Kalydeco with its experimental compound VX-089 in the treatment of cystic fibrosis. Vertex said the combination significantly improved lung function in patients who carry two copies of the F508del gene mutation, the most common mutation of the genetic disease. Final results from the trial are expected mid-year. Am I the only one here invested in this company? I bought because of the promise of their hep-C drug. A buyout offer for this company is not out of the question, hopefully not too soon. MP

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next